Trial record 74 of 280 for:    impact | "Fibromyalgia"

Effect of Revival Soy on Fibromyalgia Pain

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00279942
Recruitment Status : Completed
First Posted : January 20, 2006
Last Update Posted : January 6, 2012
Physicians Pharmaceuticals, Inc.
Information provided by (Responsible Party):
Dietlind Wahner-Roedler, Mayo Clinic

Brief Summary:
Fibromyalgia is characterized by widespread pain that can lead to significant patient dysfunction and economic burden to society. The management of patients with fibromyalgia is difficult and no single treatment modality has been successful. We propose to study the effect of dietary soy supplement on quality of life associated with fibromyalgia.

Condition or disease Intervention/treatment Phase
Fibromyalgia Dietary Supplement: Soy Other: Placebo Not Applicable

Detailed Description:

Fibromyalgia syndrome is a chronic, generalized pain syndrome that affects the musculoskeletal system (1). This syndrome is typically diagnosed in patients who experience generalized musculoskeletal pain and have excessive tenderness in at least 11 of 18 specific points (2). Although the primary cause of fibromyalgia syndrome is unclear, a growing body of evidence indicates that the widespread pain associated with this syndrome is due to abnormalities in the central nervous system. Therefore, drug therapy for fibromyalgia syndrome is most often aimed at the central nervous system and includes tricyclic antidepressants, selective serotonin reuptake inhibitors, dual serotonin and norepinephrine reuptake inhibitors, analgesics, and anticonvulsants (1).

In addition to medical therapies, complementary and alternative medicine therapies have been used to treat fibromyalgia syndrome symptoms (3). Soy is a widely used dietary supplement that has not been previously tested for treating fibromyalgia syndrome.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 50 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Effect of Revival Soy on Fibromyalgia Pain
Study Start Date : May 2006
Actual Primary Completion Date : August 2006
Actual Study Completion Date : September 2006

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: Soy
A shake that contained 20 g of soy protein and 160 mg of soy isoflavone.
Dietary Supplement: Soy
Drink a shake (vanilla and chocolate taste) once a day for 6 weeks.
Other Name: Isoflavone

Placebo Comparator: Placebo
A shake that contained 20 g of milk-based protein (casein) and no isoflavone.
Other: Placebo
Drink a shake (vanilla and chocolate taste) once a day for 6 weeks.

Primary Outcome Measures :
  1. To gather preliminary data on whether dietary soy supplement can improve quality of life in patients with fibromyalgia as measured by the Fibromyalgia Impact Questionnaire (FIQ) and the Center for Epidemiologic Studies Depression Scale (CES-D). [ Time Frame: 6 Weeks ]

Secondary Outcome Measures :
  1. To assess the feasibility of recruiting 50 patients with fibromyalgia into a study of using a dietary supplement. [ Time Frame: 3 Months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 76 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Women and men age 18 - 76
  • Able to understand and sign a consent form
  • Able to participate fully in all aspects of the study
  • Currently participating in Mayo Clinic's Fibromyalgia Treatment Program

Exclusion Criteria:

  • Pregnant or lactating women
  • Allergy to soy or other study product ingredients
  • Diagnosis of bipolar disorder, schizophrenia or dementia
  • Diagnosis of diabetes mellitus or inflammatory bowel disease
  • Presently on soy product or use of soy within the last 30 days

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00279942

United States, Minnesota
Mayo Clinic
Rochester, Minnesota, United States, 55905
Sponsors and Collaborators
Mayo Clinic
Physicians Pharmaceuticals, Inc.
Principal Investigator: Dietlind L. Wahner-Roedler, M.D. Mayo Clinic

Additional Information:
Publications of Results:
Other Publications:
Responsible Party: Dietlind Wahner-Roedler, Principal Investigator, Mayo Clinic Identifier: NCT00279942     History of Changes
Other Study ID Numbers: 2155-05
First Posted: January 20, 2006    Key Record Dates
Last Update Posted: January 6, 2012
Last Verified: January 2012

Keywords provided by Dietlind Wahner-Roedler, Mayo Clinic:
Dietary Supplements
Rheumatologic Diseases
Complementary and Alternative Medicine

Additional relevant MeSH terms:
Myofascial Pain Syndromes
Muscular Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Neuromuscular Diseases
Nervous System Diseases